CNJ.TO  Cangene Cp




Life Sciences


Market Cap.


Vuru Grade


Current Price

0.00 (0.00%)

Growth Price

Undervalued by 13.88%

Stability Price

Overvalued by 22.48%

Company Metrics

  • 169 P/E
  • 2.08 P/S
  • 1.25 P/B
  • -0.15 EPS
  • 5.09% Cash ROIC
  • 1.68 Cash Ratio
  • 0 / 0% Dividend
  • 255,197.00 Avg. Vol.
  • 240.3M Market Cap.

Company Description

Cangene Corporation develops, manufactures, and commercializes therapeutics for infectious diseases or biodefence applications in the United States, Canada, and internationally. The company develops hyperimmunes, which are concentrated specialty antibody preparations made from plasma; and recombinant biopharmaceuticals that are therapeutic proteins made by introducing a particular gene into a host...

Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow


From American vein to Canadian vein
Toronto Star - Jul 18, 2014
The company's long-term goal is to open collection sites across Canada, and a fractionation plant here. In Winnipeg, Cangene Corp., which was recently acquired by Emergent BioSolutions, pays for plasma from a small group of specialized donors who have ...
Investment Analysts' Ratings Reiterations for July, 25th (ABC, ALXN, AMZN ...
Mideast Time - Jul 25, 2014
We are encouraged by the company s decision to expand BioThrax's label. We are positive on Emergent BioSolutions' acquisition of Cangene as it has significantly expanded the company's product portfolio/pipeline. We believe that the stock is fairly ...
Cangene Corp Announces FDA Approval Of Botulism Antitoxin
Reuters Key Development - Mar 25, 2013